Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 19/20 | 0.53 |
| ▸ | PRKACA | P17612 | 2/20 | 0.51 |
| ▸ | PRKACG | P22612 | 1/20 | 0.51 |
| ▸ | PRKACB | P22694 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 9/20 | 0.51 |
| ▸ | AKT2 | P31751 | 7/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.51 |
| ▸ | AKT3 | Q9Y243 | 7/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.51 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.51 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.51 |
| ▸ | PIM1 | P11309 | 2/20 | 0.51 |
| ▸ | GSK3A | P49840 | 2/20 | 0.51 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4659504 | 1.00 | AKT1 (0.53) | AKT1PRKACAPRKACGPRKACBGSK3B | |
| SCHEMBL4659446 | 0.89 | AKT1 (0.59) | AKT1PRKACAPRKACGPRKACBGSK3B | |
| SCHEMBL4791400 | 0.88 | AKT1 (0.64) | AKT1PRKACAPRKACGPRKACBGSK3B | |
| SCHEMBL4791403 | 0.88 | AKT1 (0.64) | AKT1PRKACAPRKACGPRKACBGSK3B | |
| SCHEMBL5465188 | 0.87 | AKT1 (0.63) | AKT1PRKACAPRKACGPRKACBGSK3B | |
| SCHEMBL5469889 | 0.87 | AKT1 (0.69) | AKT1GSK3BAKT2CYP3A4AKT3 | |
| SCHEMBL5469896 | 0.87 | AKT1 (0.69) | AKT1GSK3BAKT2CYP3A4AKT3 | |
| SCHEMBL4660921 | 0.84 | AKT1 (0.60) | AKT1PRKACAPRKACGPRKACBGSK3B | |
| SCHEMBL4660929 | 0.84 | AKT1 (0.60) | AKT1PRKACAPRKACGPRKACBGSK3B | |
| SCHEMBL4659522 | 0.84 | AKT1 (0.59) | AKT1PRKACAGSK3BAKT2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720855-A4 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORP (US) | 2008-12-17 | — | — | EP | claimed |
| US-20070185152-A1 | Inhibitors of akt activity | SMITHKLINE BEECHAM CORPORATION | 2007-08-09 | — | — | US | claimed |
| EP-1720855-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-15 | — | — | EP | claimed |
| WO-2005085227-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-15 | — | — | WO | claimed |
| EP-1720855-A4 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORP (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070185152-A1 | Inhibitors of akt activity | SMITHKLINE BEECHAM CORPORATION | 2007-08-09 | — | — | US | disclosed |
| EP-1720855-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005085227-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185152-A1 | Inhibitors of akt activity | AKT1, AKT1S1, AKT2 | AKT1 1/4885PRKACA 134/4885PRKACG 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.